CXCL 1-8 targeting mRNA-based therapeutic - Omega Therapeutics
Latest Information Update: 23 May 2024
At a glance
- Originator Omega Therapeutics
- Class Antineoplastics; Gene therapies; RNA
- Mechanism of Action CXC chemokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Adult respiratory distress syndrome; Asthma; Cancer; Pneumonia; Rheumatic disorders; Skin disorders